retatrutide human trials ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Retatrutide for weight loss: Study
Description
Energy improves
"Just seeing great results can boost self-esteem, confidence and body image."
FDA approved Ozempic in December 2017 as an adjunct to diet and exercise for improving glycemic control in T2D
Colombel, J
Current FDA-approved therapies include the transthyretin stabilizers tafamidis and acoramidis, and the transthyretin silencer vutrisiran
But there is so far little information on any lasting effects going on and off GLP-1 RAs
